stoxline Quote Chart Rank Option Currency Glossary
RedHill Biopharma Ltd. (RDHL)
0.4736  -0.008 (-1.72%)    05-17 16:00
Open: 0.49
High: 0.4989
Volume: 374,459
Pre. Close: 0.4819
Low: 0.4706
Market Cap: 14(M)
Technical analysis
2024-05-17 4:48:11 PM
Short term     
Mid term     
Targets 6-month :  0.58 1-year :  0.68
Resists First :  0.49 Second :  0.58
Pivot price 0.45
Supports First :  0.37 Second :  0.3
MAs MA(5) :  0.46 MA(20) :  0.44
MA(100) :  0.65 MA(250) :  0.91
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  84.2 D(3) :  86.4
RSI RSI(14): 54.1
52-week High :  3.27 Low :  0.25
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ RDHL ] has closed below upper band by 14.1%. Bollinger Bands are 82.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 65 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.5 - 0.5 0.5 - 0.5
Low: 0.46 - 0.47 0.47 - 0.47
Close: 0.47 - 0.47 0.47 - 0.48
Company Description

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Headline News

Wed, 08 May 2024
RedHill Biopharma (RDHL) Catches Eye: Stock Jumps 5.4% - Yahoo New Zealand News

Wed, 24 Apr 2024
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study - PR Newswire

Mon, 08 Apr 2024
RedHill Biopharma's Strategic Pivot and Financial Turnaround - - TipRanks

Thu, 04 Apr 2024
RedHill Biopharma Secures $1.25M in Direct Offering - - TipRanks

Wed, 03 Apr 2024
RedHill Biopharma Announces Securities Sale - - TipRanks

Thu, 21 Mar 2024
RedHill Biopharma Share Capital Increase Approved - - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers - Specialty & Generic
Shares Out 0 (M)
Shares Float 32 (M)
Held by Insiders 7.42e+009 (%)
Held by Institutions 0 (%)
Shares Short 907 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.215e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 366.2 %
Operating Margin -1 %
Return on Assets (ttm) 60.7 %
Return on Equity (ttm) -15.8 %
Qtrly Rev. Growth 6.53e+006 %
Gross Profit (p.s.) -27.72
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -36 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 16.33
Stock Dividends
Dividend 0
Forward Dividend 753640
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android